#United States #GenScript #AmMag Quatro #DNA Purification #Piscataway

GenScript's Revolutionary AmMag Quatro Mini-1100: A New Era in DNA Purification

In the ever-evolving world of biotechnology, efficiency and precision are paramount. GenScript Biotech, a renowned leader in life sciences and biologics manufacturing, has unveiled its next-generation DNA purification platform, the AmMag Quatro Mini-1100. This advanced system promises to transform the field of plasmid DNA purification by delivering exceptional yields while minimizing endotoxin levels, crucial for modern biotechnological applications.

Features of the AmMag Quatro Mini-1100

The Mini-1100 marks a significant advancement over its predecessor, the AmMag Quatro Maxi-1400, by offering an automated solution tailored for mini-scale plasmid purification. Capable of processing up to 192 samples in a single run, this high-throughput system accommodates volumes from 1 to 10 mL, ensuring that researchers can achieve consistent and high-quality results. The automation aspect plays a vital role in reducing human error, enhancing reproducibility in experiments.

As Paul Wu, Vice President of Research and Development for GenScript, stated, "The Mini-1100 launch signifies our commitment to broadening the range of automated plasmid purification solutions. It serves as a flexible and scalable option designed to meet the evolving needs of researchers."

Optimal for Diverse Applications

With its versatility, the AmMag Quatro Mini-1100 is perfectly suited for a myriad of applications, including:

• - Gene therapy research
• - Vaccine development
• - CRISPR and gene editing techniques
• - Cell line development
• - Synthetic biology

This broad applicability is essential in a time when the demand for rapid, reliable, and efficient methods of plasmid purification is on the rise across various research fields. The Mini-1100's design speaks to the modern researcher's needs, delivering high-quality, transfection-ready plasmid DNA suitable for a host of downstream applications.

The Impact on the Research Community

GenScript's AmMag product line has set new benchmarks within the space of plasmid purification. The impressive performance metrics of previous models have garnered praise from notable biotechnology firms, including TScan Therapeutics, Valent BioSciences, and Incyte. These innovators have highlighted the AmMag systems’ efficiency and reliability across critical sectors, such as cancer research, biopharmaceutical development, and sustainable agriculture.

With the introduction of the Mini-1100, GenScript not only enhances its portfolio but also strengthens collaboration within the research community. The availability of specialized systems for both mini- and maxi-prep ensures that scientists can optimize their workflows according to their unique project requirements.

Availability and Further Information

The newly launched AmMag Quatro Mini-1100 is now officially available for order. For detailed insights and further information, researchers and interested parties can visit GenScript's website, where they can explore the technical specifications, benefits, and application cases associated with this innovative purification system.

About GenScript Biotech

Founded in 2002 in Piscataway, New Jersey, GenScript Biotech Corporation has solidified its position as a leader in the biotechnology field globally. With a workforce exceeding 5,400 employees and a clientele of over 200,000 customers in 100 countries, the company's commitment to improving health through biotechnology is unwavering. Their services have been cited in more than 100,000 peer-reviewed journal articles, reflecting their impact in the scientific community.

With continued innovation like the AmMag Quatro Mini-1100, GenScript Biotech remains dedicated to advancing scientific discovery and therapeutic innovation, establishing itself as a trustworthy partner in the realm of life sciences.